{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:08:01Z","timestamp":1791983281753,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We analyzed the additional value of systematic biopsy (SB) to MR-Ultrasound fusion biopsy (MRgFbx) for detection of clinically significant prostate cancer (csPCa), as increased sampling may cause increased morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective study cohort was comprised of 1229 biopsy sessions between July 2016 and May 2020 in men who had a Prostate Imaging-Reporting and Data System (PI-RADSv2) category\u2009\u2265\u20093 lesion on 3 Tesla multiparametric MRI (3TmpMRI) and subsequent combined biopsy (CB; MRgFbx and SB) for suspected prostate cancer (PCa). Cancer detection rates (CDR) were calculated for CB, MRgFbx and SB in the study cohort and sub-cohorts stratified by biopsy history and PI-RADSv2 category. For 927 men with unilateral MR-visible lesions, SB CDR was additionally calculated for contralateral (SBc) and ipsilateral (SBi) subcohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      On CB, the CDR for csPCa was 54.8% (673\/1229). CDR for csPCa was significantly higher for MRgFbx (50.0%, CI 47.1\u201352.8%) compared to SB (35.3%, CI 32.6\u201338.1%) for all PI-RADSv2\u2009\u2265\u20093 categories (p\u2009&lt;\u2009.05). The MRgFbx CDR for PI-RADSv2 categories 3, 4, and 5 were 81.5%, 88.5%, and 95.6% respectively. For unilateral lesion cases, significantly more csPCa was detected in the SBi compared to the SBc subcohort (30.1% (279\/927) vs. 10.4%, (96\/927),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The combination of MRgFbx and SBi detected csPCa in 97.0% (480) of the 495 csPCa detected by CB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MRgFbx had a higher CDR for csPCa than SB. While CB detected more csPCa than either method alone, in patients with a PI-RADSv2 category of 5, MRgFbx approximated the performance of CB. In unilateral lesion cases, SBc provided minimal added benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00261-024-04753-3","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T20:32:45Z","timestamp":1737145965000},"page":"3784-3793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Performance of MR fusion biopsy, systematic biopsy and combined biopsy on prostate cancer detection rate in 1229 patients stratified by PI-RADSv2 score on 3T multi-parametric MRI"],"prefix":"10.1007","volume":"50","author":[{"given":"Hannah H.","family":"Riskin-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rushikesh","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey W.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ely","family":"Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard S.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"1","key":"4753_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin [Internet]. 2019 Jan 1 [cited 2019 Jul 9];69(1):7\u201334. Available from: http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"10071","key":"4753_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815\u201322.","journal-title":"Lancet."},{"issue":"1","key":"4753_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","volume":"77","author":"FJH Drost","year":"2020","unstructured":"Drost FJH, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol. 2020 Jan 1;77(1):78\u201394.","journal-title":"Eur Urol."},{"key":"4753_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med [Internet]. 2018 May 10 [cited 2020 Feb 26];378(19):1767\u201377. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1801993","journal-title":"N Engl J Med"},{"issue":"1","key":"4753_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.2016161124","volume":"283","author":"AB Rosenkrantz","year":"2017","unstructured":"Rosenkrantz AB, Babb JS, Taneja SS, Ream JM. Proposed adjustments to PI-RADS version 2 decision rules: Impact on prostate cancer detection. Radiology [Internet]. 2017 Apr 1 [cited 2021 May 6];283(1):119\u201329. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27783538\/","journal-title":"Radiology"},{"issue":"6","key":"4753_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.29874","volume":"122","author":"CP Filson","year":"2016","unstructured":"Filson CP, Natarajan S, Margolis DJA, Huang J, Lieu P, Dorey FJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016 Mar 15;122(6):884\u201392.","journal-title":"Cancer"},{"issue":"3","key":"4753_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.juro.2017.03.131","volume":"198","author":"S Mehralivand","year":"2017","unstructured":"Mehralivand S, Bednarova S, Shih JH, Mertan F V., Gaur S, Merino MJ, et al. Prospective Evaluation of PI-RADSTM Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. J Urol [Internet]. 2017 Sep 1 [cited 2021 May 8];198(3):583\u201390. Available from: \/pmc\/articles\/PMC7900896\/","journal-title":"J Urol"},{"key":"4753_CR8","doi-asserted-by":"publisher","first-page":"2653708","DOI":"10.1155\/2019\/2653708","volume":"2019","author":"WW Laranja","year":"2019","unstructured":"Laranja WW, Sanches BCF, Voris BRI, Alonso JCC, Sim\u00f5es FA, Rejowski RF, et al. The Biopsychosocial Burden of Prostate Biopsy at the Time of Its Indication, Procedure, and Pathological Report. Prostate Cancer [Internet]. 2019 [cited 2019 Jul 9];2019:2653708. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31057971","journal-title":"Prostate Cancer"},{"key":"4753_CR9","unstructured":"Rouvi\u00e8re O, Puech P, Renard-Penna R, Claudon M, Roy C, M\u00e8ge-Lechevallier F, et al. 2019 Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. www.thelancet.com\/oncology [Internet]. 2019 [cited 2020 Feb 29];20. Available from: www.thelancet.com\/oncology"},{"issue":"10","key":"4753_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med [Internet]. 2020 Mar 5 [cited 2020 Sep 20];382(10):917\u201328. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1910038","journal-title":"N Engl J Med"},{"issue":"4","key":"4753_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000296290","volume":"84","author":"A Simsir","year":"2010","unstructured":"Simsir A, Kismali E, Mammadov R, Gunaydin G, Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int [Internet]. 2010 [cited 2020 Mar 21];84(4):395\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20224265","journal-title":"Urol Int"},{"issue":"2","key":"4753_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.juro.2018.09.042","volume":"201","author":"S Loeb","year":"2019","unstructured":"Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance. J Urol [Internet]. 2019 Feb [cited 2019 Jul 10];201(2):292\u20139. Available from: http:\/\/www.jurology.com\/doi\/https:\/\/doi.org\/10.1016\/j.juro.2018.09.042","journal-title":"J Urol"},{"issue":"4","key":"4753_CR13","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1097\/01.ju.0000116449.01186.f7","volume":"171","author":"AP Berger","year":"2004","unstructured":"Berger AP, Gozzi C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: A comparison among 3 protocols with 6, 10 and 15 cores. J Urol. 2004;171(4):1478\u201381.","journal-title":"J Urol."},{"issue":"1","key":"4753_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1109\/TBME.2018.2828304","volume":"66","author":"A Priester","year":"2024","unstructured":"Priester A, Wu H, Khoshnoodi P, Schneider D, Zhang Z, Asvadi NH, et al. Registration Accuracy of Patient-Specific, Three-Dimensional-Printed Prostate Molds for Correlating Pathology With Magnetic Resonance Imaging. IEEE Trans Biomed Eng [Internet]. 2019 Jan 1 [cited 2024 Nov 24];66(1):14\u201322. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29993431\/","journal-title":"IEEE Trans Biomed Eng"},{"issue":"4","key":"4753_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"313","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA - J Am Med Assoc. 2015 Jan 27;313(4):390\u20137.","journal-title":"JAMA - J Am Med Assoc."},{"key":"4753_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;","journal-title":"N Engl J Med."},{"issue":"9","key":"4753_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","volume":"154","author":"FF Elkhoury","year":"2019","unstructured":"Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, et al. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg. 2019 Sep 1;154(9):811\u20138.","journal-title":"JAMA Surg."},{"issue":"4","key":"4753_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.eururo.2013.03.025","volume":"65","author":"GA Sonn","year":"2014","unstructured":"Sonn GA, Chang E, Natarajan S, Margolis DJ, MacAiran M, Lieu P, et al. Value of Targeted Prostate Biopsy Using Magnetic Resonance\u2013Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. Eur Urol [Internet]. 2014 Apr [cited 2021 Dec 28];65(4):809. Available from: \/pmc\/articles\/PMC3858524\/","journal-title":"Eur Urol"},{"issue":"1","key":"4753_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00345-022-04244-4","volume":"41","author":"R Diamand","year":"2023","unstructured":"Diamand R, Peltier A, Roche JB, Lievore E, Lacetera V, Chiacchio G, et al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and prostate cancer grading accuracy. World J Urol [Internet]. 2023 Jan 1 [cited 2023 Dec 12];41(1):77\u201384. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00345-022-04244-4","journal-title":"World J Urol"},{"issue":"13","key":"4753_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/pros.24585","volume":"83","author":"I Yusim","year":"2023","unstructured":"Yusim I, Mazor E, Frumkin E, Jabareen M, Hefer B, Elsaraya N, et al. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI\/ultrasound fusion prostate biopsy. Prostate [Internet]. 2023 Sep 1 [cited 2023 Dec 12];83(13):1255\u201362. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1002\/pros.24585","journal-title":"Prostate"},{"issue":"6","key":"4753_CR21","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00261-023-03894-1","volume":"48","author":"M Ruan","year":"2023","unstructured":"Ruan M, Wang H, Li X, Song G. Novel sampling scheme with reduced cores in men with multiparametric MRI-visible lesions undergoing prostate biopsy. Abdom Radiol [Internet]. 2023 Jun 1 [cited 2023 Dec 12];48(6):2139\u201347. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00261-023-03894-1","journal-title":"Abdom Radiol"},{"key":"4753_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221111410","author":"A Jager","year":"2022","unstructured":"Jager A, van Riel LAMJG, Postema AW, de Reijke TM, van der Sluis TM, Oddens JR. An optimized prostate biopsy strategy in patients with a unilaterallesion on prostate magnetic resonance imaging avoids unnecessarybiopsies. Ther Adv Urol [Internet]. 2022 [cited 2023 Dec 12];14. Available from: \/pmc\/articles\/PMC9340407\/","journal-title":"Ther Adv Urol"},{"issue":"102","key":"4753_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.urology.2016.11.017","volume":"1","author":"DJ Bryk","year":"2017","unstructured":"Bryk DJ, Llukani E, Taneja SS, Rosenkrantz AB, Huang WC, Lepor H. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology. 2017 Apr 1;102:178\u201382.","journal-title":"Urology"},{"issue":"1","key":"4753_CR24","first-page":"37","volume":"21","author":"I Andras","year":"2019","unstructured":"Andras I, Crisan D, Cata E, Tamas-Szora A, Caraiani C, Coman R-T, et al. MRI-TRUS fusion guided prostate biopsy \u2013 initial experience and assessment of the role of contralateral lobe systematic biopsy. Med Ultrason [Internet]. 2019 Feb 17 [cited 2023 Dec 12];21(1):37\u201344. Available from: https:\/\/medultrason.ro\/medultrason\/index.php\/medultrason\/article\/view\/1705","journal-title":"Med"},{"issue":"10","key":"4753_CR25","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1007\/s00261-021-03179-5","volume":"46","author":"C Song","year":"2021","unstructured":"Song C, Park SY. Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging. Abdom Radiol [Internet]. 2021 Oct 1 [cited 2024 Feb 20];46(10):4974\u201383. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00261-021-03179-5","journal-title":"Abdom Radiol"},{"issue":"3","key":"4753_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00261-022-03775-z","volume":"48","author":"TE Phelps","year":"2023","unstructured":"Phelps TE, Yilmaz EC, Harmon SA, Belue MJ, Shih JH, Garcia C, et al. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions. Abdom Radiol [Internet]. 2023 Mar 1 [cited 2023 Dec 12];48(3):1079\u201389. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00261-022-03775-z","journal-title":"Abdom Radiol"},{"key":"4753_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001832","author":"AG Raman","year":"2021","unstructured":"Raman AG, Sarma K V., Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, et al. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. J Urol [Internet]. 2021 Apr 28 [cited 2021 May 11];JU.0000000000001832. Available from: http:\/\/www.jurology.com\/doi\/https:\/\/doi.org\/10.1097\/JU.0000000000001832","journal-title":"J Urol"},{"issue":"3","key":"4753_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","volume":"82","author":"WG Brisbane","year":"2024","unstructured":"Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER, et al. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. Eur Urol [Internet]. 2022 Sep 1 [cited 2024 Feb 20];82(3):303\u201310. Available from: http:\/\/www.europeanurology.com\/article\/S0302283822000100\/fulltext","journal-title":"Eur Urol"},{"issue":"3","key":"4753_CR29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/bju.14943","volume":"125","author":"SR Zhou","year":"2020","unstructured":"Zhou SR, Priester AM, Jayadevan R, Johnson DC, Yang JJ, Ballon J, et al. Using spatial tracking with magnetic resonance imaging\/ultrasound-guided biopsy to identify unilateral prostate cancer. BJU Int [Internet]. 2020 Mar 1 [cited 2021 May 8];125(3):399\u2013406. Available from: \/pmc\/articles\/PMC7444382\/","journal-title":"BJU Int"},{"issue":"2","key":"4753_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.juro.2017.08.085","volume":"199","author":"N Nassiri","year":"2018","unstructured":"Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, et al. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging\/Ultrasound Fusion Biopsy. J Urol [Internet]. 2018 Feb 1 [cited 2021 May 8];199(2):453\u20138. Available from: \/pmc\/articles\/PMC5780241\/","journal-title":"J Urol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-024-04753-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:49:52Z","timestamp":1757130592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-024-04753-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4753"],"URL":"https:\/\/doi.org\/10.1007\/s00261-024-04753-3","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Lu: Consultant, Medtronic plc Speaker, Medtronic plc Consultant, Johnson & Johnson Research Grant, Johnson & Johnson Consultant, Bayer AG Research Grant, Bayer AG Speaker, Bayer AG Leonard Marks: Founder, Avenda Health Steven Raman: Consultant, Johnson & Johnson Consultant, Bayer AG Consultant, Merck & Co, Inc Consultant, Amgen Inc Consultant, Profound Medical Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}